This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.

CME Available: https://auau.auanet.org/content/novel-agents-concepts-management-hormone-na%C3%AFve-castrate-resistant-prostate-cancer-webcast